neuroprotection and repair

Discussions on the newest therapeutic approaches to protection and treatment of neurological disease and injury
Attended by leading business, research, clinical and investment professionals within neuroscience
One-to-one business partnering meetings program
Great Island hospitality and culinary experience
+ show speakers and program
Tom Blackburn, Ph.D., DSc.
Founder & CEO Translational Pharmaceutical Bioventures LLC (TPBioventures)
Dr. Tom Blackburn is a graduate of Manchester University, with over 25 years of experience at senior research management and executive level with international experience in drug discovery research in the Pharmaceutical/Biotechnology sectors and proven skills in discovery of innovative therapeutics for the treatment CNS disorders. His in-depth experience combines various research disciplines and approaches in coordinating drug discovery research at different levels of integration in order to document a proof of concept for new drug candidates. His innate ability to create original concepts and manage progress to commercialization has led to major blockbuster products. He has developed original compounds to POC, IND/NDA for the treatment of migraine, analgesia, anxiety and depression, Parkinson’s disease and several POC compounds for neurodegenerative and cognitive disorders, obesity and epilepsy. Tom has published over 200 papers, abstracts, chapters and presentations in the field of neuroscience and is an inventor on over 21 patents. He was President of the British Pharmacological Society, member of the American College of Neuropsychopharmacology and the Institute of Directors (IOD, London). TPBioventures website, click here.
Screen Shot 2013-12-18 at 9.32.49 AMDale Corbett, Ph.D.
CEO and Scientific Director, Canadian Partnership for Stroke Recovery
Dr. Dale Corbett is currently a Professor of Neurosciences in the Department of Cellular and Molecular Medicine at the University of Ottawa and Scientific Director and CEO of the Heart and Stroke Foundation Canadian Partnership for Stroke Recovery. Prior to his relocation to the University of Ottawa in September 2010, Dr. Corbett held a Tier I Canada Research Chair in Stroke and Neuroplasticity at Memorial University. Dr. Corbett obtained his PhD from Concordia University followed by post-doctoral studies at McGill University. Subsequently, Dr. Corbett was a faculty member at Harvard University and also an Alfred P. Sloan Research Fellow from 1980-85. His laboratory is well known for pioneering research on the protective effects of prolonged, mild hypothermia that culminated in the use of “therapeutic hypothermia ” in the treatment of cardiac arrest and stroke. His current research concerns recovery of sensory-motor and cognitive function following stroke where he has made pivotal translational discoveries regarding the importance of early and intensive rehabilitation. Related work focuses on exercise and cognition and metabolic and vascular consequences of obesity and a sedentary lifestyle. Dr. Corbett has served on a number of peer review and research advisory committees for the Heart and Stroke Foundation and Canadian Institutes of Health Research (CIHR). He was the first recipient of the Paul Morley Mentorship Award from Canadian Stroke Network in recognition of his outstanding contributions to training new investigators in the stroke research field. His research is funded by CIHR; the Heart and Stroke Foundation; the Canadian Stroke Network and the Natural Sciences and Engineering Research Council of Canada (NSERC). He has published extensively in leading Neuroscience journals devoted to brain injury and repair.
Screen Shot 2013-12-13 at 12.07.00 PMH. Christian Fibiger, Ph.D.
Assistant Dean, Research, University of British Columbia Chief Scientific Officer, MedGenensis Therapeutix
H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from Princeton University in 1970. Dr. Fibiger was formerly the Chief Scientific Officer for Biovail Laboratories International (now Valeant). From 2003 until 2007 he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen’s worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver. He has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Fibiger serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology. MedGenesis Therapeutics website, click here.
Screen Shot 2013-10-21 at 1.50.51 PMCharles K. Meshul. Ph.D.
Oregon Health & Science University Professor, Department of Behavioral Neuroscience and Pathology (OHSU) Research Biologist and Director, Electron Microscopy Facility (VA)
Dr. Meshul’s laboratory is mainly involved in investigating electron microscopic/immunocytochemical changes in synapses within the brain following various drug treatment procedures or lesions of the nigrostriatal pathway, as a model for Parkinson’s disease (PD), and correlating these findings with functional/protein changes using in vivo microdialysis/westerns and motor behaviors in both rats and mice. Using a new progressive mouse model of PD, by administering increased doses of the toxin, MPTP, they have found that exposure of mice to a socially enriched environment can, after the initiation of the loss of dopamine, slow down or block the neurochemical and motor behavioral deficits due to continued treatment with MPTP. They are currently investigating the therapeutic affects of treadmill exercise in this same progressive MPTP model of PD in both young and aged mice.

13 Jul - 15 Jul 2014
Prince Edward Island
meeting website